<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04807582</url>
  </required_header>
  <id_info>
    <org_study_id>19CX5551</org_study_id>
    <nct_id>NCT04807582</nct_id>
  </id_info>
  <brief_title>Measuring Fatty Acid Oxidation in Cerebral Metastases Using [18F]FPIA</brief_title>
  <official_title>Determining the Magnitude of Early Steps of Fatty Acid Oxidation in Cerebral Metastases Using [18F]FPIA PET/MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cerebral metastases represent a significant problem for oncological management. It is&#xD;
      estimated that 20-40% of patients with cancer will develop metastatic cancer to the brain&#xD;
      during the course of their illness. 18F-fluoropivalate ([18F]FPIA) is a new tracer that&#xD;
      images short chain fatty acid (SCFA) uptake in tumours, a key component of fatty acid&#xD;
      oxidation.&#xD;
&#xD;
      The aim of this study is to quantify the degree of early step fatty acid oxidation in&#xD;
      cerebral metastases as imaged by [18F]FPIA Positron Emission Tomography (PET)/Magnetic&#xD;
      Resonance Imaging (MRI).&#xD;
&#xD;
      The investigators hypothesise that FPIA uptake will be higher in metastases that are&#xD;
      treatment naïve compared to those that have undergone treatment, in keeping with viable&#xD;
      tumour cells having a high propensity to generate ATP and NADPH via fatty acid oxidation&#xD;
      under bioenergetic stress.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      24 evaluable patients with radiological evidence of cerebral metastases on MRI will be&#xD;
      enrolled into the study (12 who are treatment naïve + 12 who have completed Stereotactic&#xD;
      Radiosurgery (SRS)+/- combination therapy). The patients invited to participate in the study&#xD;
      will provide written informed consent. [18F]FPIA PET/MRI imaging will only be performed once&#xD;
      patients have satisfied the inclusion and exclusion criteria. Once these have been satisfied,&#xD;
      eligible patients will proceed to [18F]FPIA PET/MRI.&#xD;
&#xD;
      On the day of imaging the patients will undergo a blood test to measure plasma concentrations&#xD;
      of carnitine (approximately 6mls). During the scan, a single dose of [18F]FPIA (maximum, 370&#xD;
      MBq) IV will be administered to the participant followed by a whole brain dynamic PET/MRI&#xD;
      scan over 66 minutes. During the MRI sequences, the patient will receive a 2 stage IV bolus&#xD;
      of Gadolinium contrast medium administered through a peripheral venous cannula.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 25, 2020</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Quantitative measurement of [18F]FPIA uptake within the cerebral metastases of treatment naïve patients.</measure>
    <time_frame>Baseline</time_frame>
    <description>PET/MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantitative measurement of [18F]FPIA uptake within the cerebral metastases of patients treated with stereotactic radiosurgery (SRS).</measure>
    <time_frame>4-8 weeks post-SRS treatment</time_frame>
    <description>PET/MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distribution of [18F]FPIA uptake in lesions which have undergone treatment, with those that are treatment naïve.</measure>
    <time_frame>At study completion, average of 1 year.</time_frame>
    <description>PET/MRI</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Correlation of [18F]FPIA variables with volumetric and functional MRI variables including perfusion.</measure>
    <time_frame>At study completion, average of 1 year.</time_frame>
    <description>PET/MRI</description>
  </other_outcome>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Cerebral Metastases</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PET/MRI</intervention_name>
    <description>18F-fluoropivalate tracer injection followed by PET/MRI scan</description>
    <other_name>Imaging Scan</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample taken for carnitine analysis.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with radiological evidence of cerebral metastases on MRI that are either treatment&#xD;
        naïve or have been treated with SRS +/- combination therapy within 4-8 weeks.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        A) Treatment naïve&#xD;
&#xD;
        or&#xD;
&#xD;
        B) SRS+/- combination treated - Patients that have completed the SRS part of a combination&#xD;
        regime enabling a 4-8 week post-SRS treatment PET/MRI scan.&#xD;
&#xD;
        and&#xD;
&#xD;
        C) That fulfil the following criteria:&#xD;
&#xD;
          1. Age ≥18.&#xD;
&#xD;
          2. Target metastases size ≥ 1cm.&#xD;
&#xD;
          3. WHO performance status 0 - 2.&#xD;
&#xD;
          4. If female, the subject is either post-menopausal (at least 1 year), or surgically&#xD;
             sterilized (has had a documented bilateral oophorectomy and/or documented hysterectomy&#xD;
             for at least 2 years), or if of childbearing potential, must have a negative urine&#xD;
             beta human chorionic gonadotropin (beta-hCG) pregnancy test done prior to tracer&#xD;
             administration.&#xD;
&#xD;
          5. The subject is able and willing to comply with study procedures, and signed and dated&#xD;
             informed consent is obtained.&#xD;
&#xD;
          6. The subject has a satisfactory medical history as judged by the investigator with no&#xD;
             significant co-morbidities.&#xD;
&#xD;
          7. The subject's clinical and laboratory tests are within normal limits and/or considered&#xD;
             clinically insignificant.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The subject is pregnant or lactating.&#xD;
&#xD;
          2. Any other chronic illness that will or musculoskeletal condition that would not allow&#xD;
             comfortable performance of a PET study.&#xD;
&#xD;
          3. Prior use within 14 days of enrolment or concurrent therapy with any other&#xD;
             investigational agent.&#xD;
&#xD;
          4. Unsatisfactory renal function (eGFR&lt;30).&#xD;
&#xD;
          5. The subject has non-MRI compatible devices (e.g.a pacemaker, an implantable&#xD;
             cardioverter-defibrillator (ICD), a nerve stimulator, a cochlear implant or a drug&#xD;
             pump) or implanted material (e.g. non-MRI compatible sternal wires, biostimulators,&#xD;
             metals or alloys).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shah Islam, MBBS FRCR</last_name>
    <phone>0203 313 3720</phone>
    <email>s.islam@imperial.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura McLeavy, MSc</last_name>
    <phone>0203 313 3720</phone>
    <email>laura.mcleavy13@imperial.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shah Islam, MBBS FRCR</last_name>
      <phone>0203 313 3720</phone>
      <email>s.islam@imperial.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Laura McLeavy, MSc</last_name>
      <phone>0203 313 3720</phone>
      <email>laura.mcleavy13@imperial.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Matthew Williams, FRCR PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shah Islam, MBBS FRCR</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>March 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2021</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PET/MRI</keyword>
  <keyword>Fatty Acid Oxidation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

